Understanding Endorphin Blockade: Why Some Patients Feel Worse Before They Feel Better on LDN

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Function Medicine Physician

• www.directintegrativecare.com

Introduction

One of the most common questions I encounter in my LDN practice—and in the LDN Support Group community of over 9,000 members—is this: “Why do I feel worse when I first start LDN?” The answer lies in understanding what LDN actually does at the receptor level and, importantly, what happens to your body’s natural endorphin system during that initial window of opioid receptor blockade.

While “endorphin blockade” is not a formal medical diagnosis, the concept describes a real physiological phenomenon: the temporary reduction in endorphin signaling that occurs when naltrexone occupies opioid receptors. For most patients, this is a brief and manageable transition. For a subset—particularly those who may already have low baseline endorphin activity—the experience can be more pronounced and sometimes discouraging.

Endorphins: A Brief Primer

Endorphins—short for “endogenous morphines”—are a family of neuropeptides produced primarily in the pituitary gland and hypothalamus. The human body produces over 20 types of endorphins, with beta-endorphin being the most potent and clinically studied. Endorphins bind to mu-, delta-, and kappa-opioid receptors throughout the central nervous system, peripheral nervous system, gastrointestinal tract, and on lymphocytes and other immune cells (Hegadoren et al., 2009; Sprouse-Blum et al., 2010).

Endorphins serve several critical functions: they modulate pain perception, regulate mood and emotional tone, support stress resilience, influence immune function, and play a role in cell proliferation and tissue repair through the opioid growth factor (OGF) pathway first described by Zagon and McLaughlin (1983). When endorphin activity is adequate, individuals experience a sense of well-being, manageable pain thresholds, and emotional stability.

What Happens When Endorphin Activity Is Low?

While endorphin deficiency is not easily measured with standard blood tests, it is clinically recognized through a characteristic pattern of symptoms. The Cleveland Clinic and multiple academic sources describe the following as hallmarks of low endorphin activity:

Common Symptoms of Low Endorphin Activity

Research by Chavkin and Bohn (2020) and Lener and Iosifescu (2019) has established a meaningful connection between endogenous opioid system dysfunction and mood disorders, including major depressive disorder and anxiety. Beta-endorphin deficiency has also been linked to PTSD-like states, with significantly lowered amygdalar beta-endorphin levels found in animal models of post-traumatic stress (Mul et al., 2018).

How LDN Works: Intermittent Blockade and the Endorphin Rebound

Naltrexone is a non-selective opioid receptor antagonist that blocks mu-, delta-, and (to a lesser extent) kappa-opioid receptors. At standard addiction-treatment doses (50–150 mg/day), naltrexone produces continuous receptor blockade—preventing endorphin signaling for 24 hours or longer. At low doses (typically 0.5–4.5 mg), however, the pharmacodynamics change fundamentally.

LDN binds to opioid receptors for approximately 1–1.5 hours, and the functional blockade lasts only 4–6 hours (LDN Research Trust; Younger et al., 2014). During this blockade window, the body’s endorphins cannot access their receptors. The hypothalamus, sensing this endorphin “deficit,” responds by upregulating endorphin production—a compensatory response termed the endorphin rebound effect. Simultaneously, the body increases the number and sensitivity of opioid receptors (Tempel et al., 1985; Zukin et al., 1982).

Once LDN is metabolized and clears the receptors, the elevated endorphins—now with more and more sensitive receptors available—produce enhanced endogenous opioid signaling that typically persists for 18–20 hours. This is the therapeutic window responsible for LDN’s reported benefits in pain modulation, immune regulation, and mood enhancement.

The critical distinction: Standard-dose naltrexone produces continuous opioid receptor blockade, which prevents any therapeutic rebound. LDN produces intermittent blockade, which enables the rebound effect. This is why dose matters profoundly—and why more is decidedly not better with naltrexone when the goal is immune modulation and endorphin upregulation (Zagon & McLaughlin, 1984; Younger et al., 2014).

Why Some Patients Experience Temporary Worsening on LDN

Here is the key insight that every LDN prescriber and patient should understand: during the 4–6 hour blockade window, endorphin signaling is temporarily reduced. For most people, this occurs during sleep (hence the recommendation for bedtime dosing) and goes unnoticed. However, for certain patients—especially those who are already endorphin-deficient at baseline—even this brief interruption can produce noticeable symptoms.

Populations at Higher Risk for Initial Worsening

Patients most likely to experience symptoms during the blockade window include those with chronic pain conditions (especially fibromyalgia, where baseline endorphin levels are already low), autoimmune diseases (where met-enkephalin/OGF levels are often depleted), chronic fatigue syndrome or ME/CFS, a history of depression or anxiety disorders, and those with a history of chronic stress or trauma (which depletes endorphin reserves over time).

For these individuals, the temporary blockade of already-scarce endorphin activity can manifest as transient worsening of their baseline symptoms: increased pain, worsened mood, heightened anxiety, disrupted sleep, or general malaise. This is typically self-limited and resolves as the rebound effect kicks in—but the experience can be discouraging enough to cause premature discontinuation if patients are not adequately counseled.

When the Dose Is Too High: Continuous vs. Intermittent Blockade

This is where clinical judgment becomes critical. If the LDN dose is too high for a given individual, the receptor blockade may extend beyond the 4–6 hour window, approaching the continuous blockade characteristic of standard-dose naltrexone. When this happens, the body’s compensatory mechanisms cannot keep up, and the beneficial rebound effect is compromised.

As the LDN Research Trust notes, high doses or sustained-release formulations result in continuous blockade of OGF receptors, and the rebound effect will not serve any useful purpose. Zagon and McLaughlin (1984) demonstrated in preclinical models that only intermittently administered low-dose naltrexone generates an anti-tumor response—high doses that produce continuous blockade actually promoted tumor growth.

Signs That the LDN Dose May Be Too High

Clinicians from the LDN Research Trust describe a practical indicator: if the patient feels as though they have had too much caffeine—overstimulated, anxious, jittery—the dose should be reduced by 0.5 mg. Other signs include persistent (rather than transient) worsening of mood, unremitting insomnia or vivid dreams that do not resolve within 1–2 weeks, sustained increase in pain sensitivity, and new-onset anxiety or irritability that does not abate.

The solution is straightforward: reduce the dose by 0.5 mg and reassess. Many patients who fail at 4.5 mg do well at 3.0 or even 1.5 mg. The “sweet spot” is highly individual. In my practice, I routinely start patients at 0.5–1.0 mg and titrate upward by 0.5 mg every 1–2 weeks, closely monitoring symptom response.

A Note on Evolving Science

It is important to acknowledge that the endorphin rebound hypothesis, while clinically compelling and supported by receptor upregulation data (Tempel et al., 1985; Lahti & Collins, 1978; Zukin et al., 1982), has been questioned by some recent research. Bhatt et al. (2021) published in eNeuro that LDN did not significantly alter POMC neuron activity or beta-endorphin release in the arcuate nucleus of mice, suggesting that LDN’s mood-enhancing effects may operate through mechanisms independent of the classical beta-endorphin system.

This does not invalidate the clinical observations—patients unquestionably report the pattern described above. Rather, it suggests that LDN’s therapeutic effects likely involve multiple pathways, including Toll-like receptor 4 (TLR4) antagonism and microglial modulation (Younger et al., 2014), OGF-OGFr axis modulation (Zagon & McLaughlin, multiple publications), endorphin/enkephalin rebound effects at receptors beyond the arcuate nucleus, and immune cell opioid receptor modulation (T-cell and B-cell regulation). The takeaway for clinicians is that while the endorphin rebound model remains a useful clinical framework for counseling patients, the complete mechanism of LDN is likely more nuanced and multifactorial than any single pathway can explain.

Clinical Pearls for Managing Endorphin Blockade Symptoms

1. Counsel patients proactively. Inform patients before starting LDN that temporary worsening of symptoms is possible and does not mean the medication is harmful—it means the body is responding to the transient receptor blockade.

2. Start low and go slow. Begin at 0.5–1.0 mg nightly and titrate by 0.5 mg every 1–2 weeks. There is no rush to reach 4.5 mg, and many patients achieve optimal benefit at lower doses.

3. Adjust timing if needed. While bedtime dosing is standard, approximately one-third of patients tolerate morning dosing better—particularly those who experience vivid dreams or insomnia.

4. Reduce dose if symptoms persist beyond 2 weeks. Transient side effects should resolve within the first 1–2 weeks. Persistent symptoms suggest the dose exceeds the patient’s optimal intermittent blockade threshold.

5. Avoid sustained-release formulations. These convert the intermittent blockade into continuous blockade and negate the therapeutic rebound effect.

6. Identify baseline endorphin-depleted patients. Those with fibromyalgia, chronic fatigue, autoimmune disease, chronic pain, depression, or history of trauma may need even gentler titration (starting at 0.25–0.5 mg).

Conclusion

The temporary worsening that some patients experience when initiating LDN is not a sign of drug intolerance or treatment failure—it is an expected pharmacological consequence of opioid receptor blockade in individuals with low baseline endorphin activity. By understanding the difference between intermittent and continuous blockade, prescribers can titrate intelligently, counsel patients effectively, and avoid the premature abandonment of a therapy that, for many, becomes transformative once the optimal dose is identified.

As with all aspects of integrative medicine, the guiding principle remains: marry the result, not the method. If a patient is not tolerating a given dose, the method is wrong—not the patient.

References

1. Bhatt DK, Gupta S, Ploug KB, et al. Reported benefits of low-dose naltrexone appear to be independent of the endogenous opioid system involving proopiomelanocortin neurons and β-endorphin. eNeuro. 2021;8(3):ENEURO.0087-21.2021. doi:10.1523/ENEURO.0087-21.2021

2. Chavkin C, Bohn LM. The role of the endogenous opioid system in the neurobiology of depression. Br J Pharmacol. 2020;177(3):543–551. doi:10.1111/bph.14879

3. Cleveland Clinic. Endorphins: What they are and how to boost them. Updated February 2026. https://my.clevelandclinic.org/health/body/23040-endorphins

4. Hegadoren KM, O’Donnell T, Lanius R, Coupland NJ, Bhagwagar Z. The role of beta-endorphin in the pathophysiology of major depression. Neuropeptides. 2009;43(5):341–353. doi:10.1016/j.npep.2009.06.004

5. Lahti RA, Collins RJ. Chronic naloxone results in prolonged increases in opiate binding sites in brain. Eur J Pharmacol. 1978;51(2):185–186. doi:10.1016/0014-2999(78)90346-6

6. Lener MS, Iosifescu DV. The opioid system in mood and anxiety disorders: a review of emerging research and therapeutic implications. Transl Psychiatry. 2019;8(1):227.

7. LDN Research Trust. What is low dose naltrexone (LDN)? https://ldnresearchtrust.org/what-is-low-dose-naltrexone-ldn

8. LDNscience.org. How does low dose naltrexone (LDN) work? https://www.ldnscience.org/ldn/how-does-ldn-work

9. Sprouse-Blum AS, Smith G, Sugai D, Parsa FD. Understanding endorphins and their importance in pain management. Hawaii Med J. 2010;69(3):70–71.

10. Tempel A, Gardner EL, Zukin RS. Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation. J Pharmacol Exp Ther. 1985;232(2):439–444. PMID: 2982011

11. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2

12. Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in mice with neuroblastoma. Science. 1983;221(4611):671–673. doi:10.1126/science.6867737

13. Zagon IS, McLaughlin PJ. Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid systems in cancer. Life Sci. 1984;35(4):409–416. doi:10.1016/0024-3205(84)90652-2

14. Zagon IS, McLaughlin PJ. Intermittent blockade of OGFr and treatment of autoimmune disorders. Exp Biol Med (Maywood). 2018;243(17–18):1323–1330. doi:10.1177/1535370218817746

15. Zukin RS, Sugarman JR, Fitz-Syage ML, Gardner EL, Zukin SR, Gintzler AR. Naltrexone-induced opiate receptor supersensitivity. Brain Res. 1982;245(1):185–192. doi:10.1016/0006-8993(82)90352-0

© 2026 Direct Integrative Care. All rights reserved.

www.directintegrativecare.com